Overview

Efficacy and Safety of Inhaled Bronchodilator in Non-CF Bronchiectasis With Airflow Limitation

Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
0
Participant gender:
All
Summary
Airflow limitation is common exist in idiopathic bronchiectasis patients. However, there are few evidence on the treatment of bronchodilator in bronchiectasis with airflow limitation. The efficacy and safety of dual bronchodilator in idiopathic bronchiectasis with airflow limitation are still unclear. Thus, the investigators conduct a multicenter, open-label randomized controlled trial to investigate the efficacy and safety of dual bronchodilator in idiopathic bronchiectasis with airflow limitation.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Shanghai Pulmonary Hospital, Shanghai, China
Treatments:
Bronchodilator Agents
Criteria
Inclusion Criteria:

- Idiopathic bronchiectasis with FEV1/FVC < 70%

Exclusion Criteria:

- With Asthma

- α-1 antitrypsin deficiency

- Turculosis

- Lung cancer

- Sarcoidosis

- Idiopathic pulmonary fibrosis

- Primary pulmonary hypertension

- Uncontrolled sleep apnea

- Bronchiectasis accepted long-term low dose macrolides

- Pulmonary surgery within 6 months

- Lower respiratory tract infections require antibiotic treatment in 6 weeks

- Upper respiratory tract infection did not recover for at least 7 days

- With Glaucoma or severe prostate hyperplasia that can not use Indacaterol

- Patients allergic to experimental drugs

- Women pregnant, breast-feeding or who planned a pregnancy during the study